德琪医药将携3项创新研究成果亮相SITC 2024年会

中国上海和香港，2024年10月5日–致力于研发，生产和销售同类首款及/或同类最优血液及实体肿瘤疗法的商业化阶段领先创新生物制药公司–德琪医药有限公司（简称“德琪医药”，香港交易所股票代码：6996.HK）今日宣布，公司将在计划于2024年11月6日至10日在美国休斯顿市举行的2024年癌症免疫治疗学会年会（SITC 2024）上公布三项研究成果。

AnTenGager™平台是德琪医药自主研发的T细胞衔接器（TCE）平台。它可以同时结合疾病相关抗原（DAA）和T细胞表达的CD3的独特的空间表位。通过二价结合DAA，它能有效识别并清除低靶抗原表达水平的细胞。此外，AnTenGager™ TCE只在存在DAA的情况下，条件性地激活T细胞，从而降低了系统性的CD3激活和细胞因子释放综合征（CRS）的风险。这为它在治疗自身免疫性疾病、血液系统恶性肿瘤和实体瘤等领域的应用提供了可能。

公司基于AnTenGager™的产品线丰富。这些TCE旨在协同解决自身免疫性疾病和血液学/肿瘤学领域未被满足的临床需求，并有望成为同类最佳或同类首创的解决方案。目前，我们已有一些处于临床启用阶段的主要项目，当中包括ATG-201，一款用于 B 细胞相关自身免疫性疾病的CD19 x CD3 TCE；ATG-102，一款用于急性髓系白血病和慢性粒单核细胞白血病的LILRB4 x CD3 TCE；ATG-106，一款用于卵巢癌和肾癌的CDH6 x CD3 TCE；ATG-107，一款用于急性髓系白血病的FLT3 x CD3 TCE；和ATG-110，一款用于微卫星稳定（MSS）结直肠癌的LY6G6D x CD3 TCE。

本文所作出的前瞻性陈述仅与本文作出该陈述当日的事件或资料有关。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请细阅本文，并理解我们的实际未来业绩或表现可能与预期有重大差异。本文内有关任何董事或本公司意向的陈述或提述乃于本文刊发日期作出。任何该等意向均可能因未来发展而出现变动。有关这些因素和其他可能导致未来业绩与任何前瞻性声明存在重大差异的因素的进一步讨论，请参阅我们截至2023年12月31日的公司年报中描述的其他风险和不确定性，以及之后向香港证券交易所提交的文件。

The AnTenGager™ Platform is a proprietary “2+1” T cell engager (TCE) platform developed by Antengene.  AnTenGager™ TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager™ TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors.

Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer.

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

杭州医药港于2017年启动建设，2018年5月，被授予“杭州医药港”称号。经过六年发展，医药港先后获评省级特色小镇命名、全省“万亩千亿”新产业平台等，是杭州市生物医药产业发展的核心区。2023年11月，杭州市建设“中国医药港”正式在钱塘启动，翻开医药港发展的新篇章。

杭州医药港坚持“链式+集群”产业发展新模式，打造创新链、产业链、人才链、政策链、金融链、服务链“六链融合”的热带雨林式产业生态。目前，已集聚生物医药企业1700余家，默沙东等全球10大知名药企有7家落户，上市及重点拟上市企业23家，“准独角兽”企业30家，集聚谭蔚泓等16个院士团队。2023年，医药港平台全年实现工业总产值475亿元、同比增长10%